a Department of Experimental Therapeutics , The University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.
b Department of Pathology , The University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.
Autophagy. 2018;14(4):637-653. doi: 10.1080/15548627.2018.1427022. Epub 2018 Mar 21.
Among the 3 GTPases in the DIRAS family, DIRAS3/ARHI is the best characterized. DIRAS3 is an imprinted tumor suppressor gene that encodes a 26-kDa GTPase that shares 60% homology to RAS and RAP. DIRAS3 is downregulated in many tumor types, including ovarian cancer, where re-expression inhibits cancer cell growth, reduces motility, promotes tumor dormancy and induces macroautophagy/autophagy. Previously, we demonstrated that DIRAS3 is required for autophagy in human cells. Diras3 has been lost from the mouse genome during evolutionary re-arrangement, but murine cells can still undergo autophagy. We have tested whether DIRAS1 and DIRAS2, which are homologs found in both human and murine cells, could serve as surrogates to DIRAS3 in the murine genome affecting autophagy and cancer cell growth. Similar to DIRAS3, these 2 GTPases share 40-50% homology to RAS and RAP, but differ from DIRAS3 primarily in the lengths of their N-terminal extensions. We found that DIRAS1 and DIRAS2 are downregulated in ovarian cancer and are associated with decreased disease-free and overall survival. Re-expression of these genes suppressed growth of human and murine ovarian cancer cells by inducing autophagy-mediated cell death. Mechanistically, DIRAS1 and DIRAS2 induce and regulate autophagy by inhibition of the AKT1-MTOR and RAS-MAPK signaling pathways and modulating nuclear localization of the autophagy-related transcription factors FOXO3/FOXO3A and TFEB. Taken together, these data suggest that DIRAS1 and DIRAS2 likely serve as surrogates in the murine genome for DIRAS3, and may function as a backup system to fine-tune autophagy in humans.
在 DIRAS 家族的 3 个 GTPases 中,DIRAS3/ARHI 的特征最为明显。DIRAS3 是一种印迹肿瘤抑制基因,编码一种 26kDa 的 GTPase,与 RAS 和 RAP 有 60%的同源性。DIRAS3 在许多肿瘤类型中下调,包括卵巢癌,其中重新表达可抑制癌细胞生长、降低迁移性、促进肿瘤休眠并诱导巨自噬/自噬。之前,我们证明 DIRAS3 是人类细胞自噬所必需的。在进化重排过程中,DIRAS3 已从小鼠基因组中丢失,但小鼠细胞仍能进行自噬。我们已经测试了人类和小鼠细胞中存在的同源物 DIRAS1 和 DIRAS2 是否可以作为 DIRAS3 在影响自噬和癌细胞生长的小鼠基因组中的替代物。与 DIRAS3 相似,这 2 个 GTPases 与 RAS 和 RAP 的同源性为 40-50%,但与 DIRAS3 的主要区别在于其 N 端延伸的长度。我们发现 DIRAS1 和 DIRAS2 在卵巢癌中下调,与无病生存期和总生存期缩短有关。这些基因的重新表达通过诱导自噬介导的细胞死亡抑制人类和小鼠卵巢癌细胞的生长。从机制上讲,DIRAS1 和 DIRAS2 通过抑制 AKT1-MTOR 和 RAS-MAPK 信号通路以及调节自噬相关转录因子 FOXO3/FOXO3A 和 TFEB 的核定位来诱导和调节自噬。综上所述,这些数据表明 DIRAS1 和 DIRAS2 可能在小鼠基因组中作为 DIRAS3 的替代物,并可能作为微调人类自噬的后备系统。